Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Multifaceted effects of hydroxychloroquine in human disease.

Olsen NJ, Schleich MA, Karp DR.

Semin Arthritis Rheum. 2013 Oct;43(2):264-72. doi: 10.1016/j.semarthrit.2013.01.001. Epub 2013 Mar 5. Review.

PMID:
23481418
2.

Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF.

Inflammopharmacology. 2015 Oct;23(5):231-69. doi: 10.1007/s10787-015-0239-y. Epub 2015 Aug 6. Review.

PMID:
26246395
3.

Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.

Abarientos C, Sperber K, Shapiro DL, Aronow WS, Chao CP, Ash JY.

Expert Opin Drug Saf. 2011 Sep;10(5):705-14. doi: 10.1517/14740338.2011.566555. Epub 2011 Mar 22. Review.

PMID:
21417950
4.

The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.

Hu C, Lu L, Wan JP, Wen C.

Curr Med Chem. 2017;24(20):2241-2249. doi: 10.2174/0929867324666170316115938. Review.

PMID:
28302011
5.

Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases.

Rekedal LR, Massarotti E, Garg R, Bhatia R, Gleeson T, Lu B, Solomon DH.

Arthritis Rheum. 2010 Dec;62(12):3569-73. doi: 10.1002/art.27703.

6.

Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.

Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, Manzi S, Wasko MC.

J Rheumatol. 2010 Jun;37(6):1136-42. doi: 10.3899/jrheum.090994. Epub 2010 May 1.

7.

Hydroxychloroquine in systemic lupus erythematosus (SLE).

Ponticelli C, Moroni G.

Expert Opin Drug Saf. 2017 Mar;16(3):411-419. doi: 10.1080/14740338.2017.1269168. Epub 2016 Dec 14. Review.

PMID:
27927040
8.

Long-term effectiveness of antimalarial drugs in rheumatic diseases.

Aviña-Zubieta JA, Galindo-Rodriguez G, Newman S, Suarez-Almazor ME, Russell AS.

Ann Rheum Dis. 1998 Oct;57(10):582-7.

9.

The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.

Mavrikakis I, Sfikakis PP, Mavrikakis E, Rougas K, Nikolaou A, Kostopoulos C, Mavrikakis M.

Ophthalmology. 2003 Jul;110(7):1321-6.

PMID:
12867385
10.

Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.

Chen YM, Lin CH, Lan TH, Chen HH, Chang SN, Chen YH, Wang JS, Hung WT, Lan JL, Chen DY.

Rheumatology (Oxford). 2015 Jul;54(7):1244-9. doi: 10.1093/rheumatology/keu451. Epub 2015 Jan 12.

PMID:
25587177
11.

Hydroxychloroquine: a multifaceted treatment in lupus.

Costedoat-Chalumeau N, Dunogué B, Morel N, Le Guern V, Guettrot-Imbert G.

Presse Med. 2014 Jun;43(6 Pt 2):e167-80. doi: 10.1016/j.lpm.2014.03.007. Epub 2014 May 19. Review.

PMID:
24855048
12.

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.

Costedoat-Chalumeau N, Amoura Z, Huong DL, Lechat P, Piette JC.

Autoimmun Rev. 2005 Feb;4(2):111-5. Epub 2004 Dec 14. Review.

PMID:
15722258
13.

Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis.

Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, Hua C.

Ann Rheum Dis. 2018 Jan;77(1):98-103. doi: 10.1136/annrheumdis-2017-211836. Epub 2017 Sep 25. Review.

PMID:
28970215
14.

Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.

Jallouli M, Francès C, Piette JC, Huong du LT, Moguelet P, Factor C, Zahr N, Miyara M, Saadoun D, Mathian A, Haroche J, De Gennes C, Leroux G, Chapelon C, Wechsler B, Cacoub P, Amoura Z, Costedoat-Chalumeau N; Plaquenil LUpus Systemic Study Group.

JAMA Dermatol. 2013 Aug;149(8):935-40. doi: 10.1001/jamadermatol.2013.709.

PMID:
23824340
15.

Discontinuation of antimalarial drugs in systemic lupus erythematosus.

Wang C, Fortin PR, Li Y, Panaritis T, Gans M, Esdaile JM.

J Rheumatol. 1999 Apr;26(4):808-15.

PMID:
10229401
16.

A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus.

Carmichael SJ, Day RO, Tett SE.

Intern Med J. 2013 May;43(5):547-53. doi: 10.1111/imj.12100.

PMID:
23425382
17.

Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study.

Diav-Citrin O, Blyakhman S, Shechtman S, Ornoy A.

Reprod Toxicol. 2013 Aug;39:58-62. doi: 10.1016/j.reprotox.2013.04.005. Epub 2013 Apr 17.

PMID:
23602891
18.

The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.

Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR.

J Rheumatol. 2013 Jun;40(6):831-41. doi: 10.3899/jrheum.120572. Epub 2013 Apr 15.

PMID:
23588942
19.
20.

Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications.

Kerr G, Aujero M, Richards J, Sayles H, Davis L, Cannon G, Caplan L, Michaud K, Mikuls T.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1619-26. doi: 10.1002/acr.22341.

Supplemental Content

Support Center